Treatment of Pain Associated With Lumbosacral Radiculopathy in Adults

NCT ID: NCT03727100

Last Updated: 2023-10-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

207 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-16

Study Completion Date

2020-07-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the safety and effectiveness of a new pain medication in development, clonidine micropellet. Participants will receive a single injection of either clonidine micropellet or sham injection for the treatment of low back and leg pain from sciatica.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lumbosacral Radiculopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Clonidine Micropellet vs Sham-Control
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Double-Blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clonidine Micropellets

single dose injection into the lumbar epidural space

Group Type ACTIVE_COMPARATOR

Clonidine Micropellets

Intervention Type COMBINATION_PRODUCT

Injection

Sham Control

non-epidural needle placement

Group Type SHAM_COMPARATOR

Sham

Intervention Type OTHER

Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clonidine Micropellets

Injection

Intervention Type COMBINATION_PRODUCT

Sham

Injection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Be between 18 and 70 years of age (inclusive) at time the Informed Consent Form (ICF) is signed.
2. Diagnosis of unilateral radicular leg pain.
3. Women of childbearing potential must have a negative pregnancy test at Screening and within 24 hours prior to procedure and commit to adequate birth control during the the study.
4. Understands the purpose and any risks associated with the procedure required for the study and is willing to participate in the study.
5. Agrees to follow study-specific medication requirements.
6. Be able to read, write, understand, and complete study-related tasks, and adequately communicate in English.
7. Subject must have failed at least one conservative therapy in two different categories.

Exclusion Criteria

1. Medical condition or radiographic evidence that, in the Investigator's opinion, could adversely impact study outcomes.
2. Received an lumbar epidural steroid injection, nerve block or similar procedure during the 4 weeks prior to Screening.
3. Female subjects who are pregnant or breastfeeding.
4. History of lumbar surgery.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lotus Clinical Research, LLC

OTHER

Sponsor Role collaborator

Sollis Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christopher Gilligan, MD

Role: PRINCIPAL_INVESTIGATOR

Brigham and Women's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sollis Clinical Study Site 36

Mobile, Alabama, United States

Site Status

Sollis Clinical Study Site #41

Phoenix, Arizona, United States

Site Status

Sollis Clinical Study Site #44

Phoenix, Arizona, United States

Site Status

Sollis Clinical Study Site 29

Scottsdale, Arizona, United States

Site Status

Sollis Clinical Study Site 40

Tucson, Arizona, United States

Site Status

Sollis Clinical Study Site 49

Rancho Mirage, California, United States

Site Status

Sollis Clinical Study Site 28

Santa Rosa, California, United States

Site Status

Sollis Clinical Study Site 30

Washington D.C., District of Columbia, United States

Site Status

Sollis Clinical Study Site 35

Fort Lauderdale, Florida, United States

Site Status

Sollis Clinical Study Site 38

Miami, Florida, United States

Site Status

Sollis Clinical Study Site 12

Bloomington, Illinois, United States

Site Status

Sollis Clinical Study Site 13

Chicago, Illinois, United States

Site Status

Sollis Clinical Study Site 14

Kansas City, Kansas, United States

Site Status

Sollis Clinical Study Site

Overland Park, Kansas, United States

Site Status

Sollis Clinical Study Site 10

Edgewood, Kentucky, United States

Site Status

Sollis Clinical Study Site 16

Boston, Massachusetts, United States

Site Status

Sollis Clinical Study Site 15

Brookline, Massachusetts, United States

Site Status

Sollis Clinical Study Site 17

Shrewsbury, New Jersey, United States

Site Status

Sollis Clinical Study Site 25

Albany, New York, United States

Site Status

Sollis Clinical Study Site 31

Rochester, New York, United States

Site Status

Sollis Clinical Study Site 18

Winston-Salem, North Carolina, United States

Site Status

Sollis Clinical Study Site 21

Cleveland, Ohio, United States

Site Status

Sollis Clinical Study Site 33

Cleveland, Ohio, United States

Site Status

Sollis Clinical Study Site 19

Edmond, Oklahoma, United States

Site Status

Sollis Clinical Study Site 46

Eugene, Oregon, United States

Site Status

Sollis Clinical Study Site

Dallas, Texas, United States

Site Status

Sollis Clinical Study Site 34

Houston, Texas, United States

Site Status

Sollis Clinical Study Site 22

San Antonio, Texas, United States

Site Status

Sollis Clinical Study Site 43

The Woodlands, Texas, United States

Site Status

Sollis Clinical Study Site 20

Tyler, Texas, United States

Site Status

Sollis Clinical Study Site 47

Salt Lake City, Utah, United States

Site Status

Sollis Clinical Study Site 23

Morgantown, West Virginia, United States

Site Status

Sollis Clinical Study Site 27

Madison, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STX-015-18-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pain Treatment for Sciatica
NCT00009672 COMPLETED PHASE2
Steroids Versus Gabapentin
NCT01495923 COMPLETED NA